Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com

Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

By Jared Kaltwasser

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Podcast: Takeaways From the 5th Annual Patient-Centered Oncology Care Meeting

February 23rd 2017

Podcast: Takeaways From the 5th Annual Patient-Centered Oncology Care Meeting

Presenters and panelists at the 5th annual Patient-Centered Oncology Care meeting provide their key takeaways.

February 23rd 2017

Lenalidomide Approved as Maintenance for Multiple Myeloma Following Transplant

The FDA has approved lenalidomide as maintenance therapy in patients with multiple myeloma following autologous stem cell transplant.

Dr Joseph Alvarnas Discusses Awareness of Cancer Patients' Financial Concerns

February 23rd 2017

Dr Joseph Alvarnas Discusses Awareness of Cancer Patients' Financial Concerns

Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology, admits that he was once “oblivious” to his patients’ concerns about the cost of cancer treatment. However, it is important for clinicians to empathize with these fears and understand how they can factor into a patient’s care choices.

February 23rd 2017

AJMC®'s Evidence-Based Oncologyâ„¢ Publishes Third Annual Immuno-Oncology Issue

The advance of CAR-T technology and the rise of immuno-oncology alongside emerging new payment models highlight the annual review in Evidence-Based Oncologyâ„¢, which looks at how researchers are harnessing the immune system to bring unprecedented results in cancer care.

February 22nd 2017

Bundled Payments and Other Cost-Management Approaches to Oncology Care

Christina Mattina

At the 5th annual Patient-Centered Oncology CareÂ® meeting, stakeholders shared their views on how bundled payments, clinical pathways, and other value-based approaches can be implemented in cancer care while ensuring adequate care quality.

February 22nd 2017

Panel Presents Unique Cost-Sharing Viewpoints in Oncology Care

Christina Mattina

Panelists from diverse vantage points in the cancer care landscape discussed the effects of cost sharing on patients in a discussion at the 5th annual Patient-Centered Oncology CareÂ® meeting.

February 22nd 2017

Integrating Patient-Centered Outcomes in APMs

Surabhi Dangi-Garimella, PhD

As payment models shift to emphasize patient experience and quality of care, a panel discussion at the 5th annual Patient-Centered Oncology CareÂ® meeting debated whether these efforts had meaningfully improved outcomes for patients.

February 22nd 2017

CVS Decision to Stop Tobacco Sales Reduced Cigarette Purchase

Surabhi Dangi-Garimella, PhD

The company's study has found a 38% drop in cigarette purchase among shoppers who visit CVS stores.

February 22nd 2017

Exercise Most Powerful Lifestyle Factor in Improving Breast Cancer Outcomes

Christina Mattina

A recent literature review, examining evidence on lifestyle changes that can reduce the risk of recurrence or death for women diagnosed with breast cancer, found that exercise can reduce the risk of both outcomes.

Samantha Watson Describes How Cancer Patients Balance Health With Finances

February 22nd 2017

Samantha Watson Describes How Cancer Patients Balance Health With Finances

As founder and CEO of The Samfund, Samantha Watson has found that most cancer patients prioritize their physical health over their financial stability, leaving them lagging behind their peers economically or even facing bankruptcy.

February 21st 2017

Age, Plan Deductible Influence Prescription Changes Among Cancer Survivors

Researchers at the American Cancer Society have found that nonelderly cancer survivors enrolled in high-deductible health plans are more likely to seek a change to a lower-cost prescription medication compared with those without a cancer history.

February 21st 2017

Specialty Pharmacies Transforming Cancer Care

Surabhi Dangi-Garimella, PhD

Specialty pharmacies can collaborate with clinical teams to harness the power of health information technology and improve cancer care, according to panelists at the 5th annual Patient-Centered Oncology CareÂ® meeting.

February 21st 2017

Cholesterol-Lowering Medications Complement Endocrine Therapy in Breast Cancer

Surabhi Dangi-Garimella, PhD

Including anti-cholesterol agents during adjuvant endocrine treatment can prevent breast cancer recurrence in hormone receptor—positive early-stage breast cancer.

February 20th 2017

TAPUR Trial Expands Who Can Join Clinical Trials, If Payers Fund Genomic Tests

Pam Mangat, MS, associate director for the TAPUR study in the research and analysis division of the American Society of Clinical Oncology, offered an update on the study at the 5th annual Patient-Centered Oncology CareÂ® meeting.

February 20th 2017

Developments in Immunotherapy at PCOC®: The Living Drugs

Surabhi Dangi-Garimella, PhD

David L. Porter, MD, kicked off the 5th annual Patient-Centered Oncology CareÂ® (PCOCÂ®) meeting in Baltimore on November 17, 2016, with an update on chimeric antigen receptor T-cell therapy.

February 20th 2017

Responding to Patient Needs Central to Providing Value in Cancer Care

Christina Mattina

At the 5th annual Patient-Centered Oncology CareÂ® meeting, Nell Wood Buhlman of Press Ganey explained that oncology providers must focus on patient needs and minimize suffering in order to truly provide value in cancer care.

February 20th 2017

Immunoâ€Oncology Versus Precision Medicine: Where Is Cancer Care Headed?

Surabhi Dangi-Garimella, PhD

At the 5th annual Patient-Centered Oncology CareÂ® meeting, hosted by The American Journal of Managed CareÂ®, experts discussed the contradiction presented by immuno-oncology agents in the world of precision medicine.

February 20th 2017

The Future of Oncology Care: 2017 and Beyond

Christina Mattina

Bruce A. Feinberg, DO, moderated a panel at the 5th annual Patient-Centered Oncology CareÂ® meeting that brought stakeholders together to share their cancer care predictions for the upcoming year.

February 20th 2017

Cancer Trial Participants Can Successfully Self-Report Adverse Events

Christina Mattina

Adverse events from cancer clinical trials are currently reported by trial investigators, but a recent feasibility study found that patients can successfully and accurately report their own symptoms if given the opportunity.

February 19th 2017

OlympiAD Trial Reports Success With Olaparib and Predictive Diagnostic Test

Surabhi Dangi-Garimella, PhD

The trial successfully improved progression-free survival and also tested a BRCA diagnostic test in patients with ovarian cancer.

Dr Carrie Stricker on How Carevive Integrates Patient-Reported Outcomes Into Care Planning

February 19th 2017

Dr Carrie Stricker on How Carevive Integrates Patient-Reported Outcomes Into Care Planning

Carevive recognizes the importance of including patient-reported outcomes into the care planning process, so they have developed surveys that will provide patients with the resources to address those concerns, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

February 17th 2017

Pharma—PBM War on Drug Prices Picks Up Steam

Surabhi Dangi-Garimella, PhD

An e-mail, from Mark Merritt, president and CEO of the trade group Pharmaceutical Care Management Association, to the organization’s board, lays out a plan to develop an aggressive campaign to convince the new administration that the fault rests with pharmaceutical manufacturers.

This Week in Managed Care: February 17, 2017

February 17th 2017

This Week in Managed Care: February 17, 2017

This week, the top managed care stories included the end of 2 insurance megamergers, a proposed rule to tighten restrictions for the Affordable Care Act, and new legislation in New Jersey provides the nation's strictest mandates for treating addiction.

Pam Mangat on the Future of Surrogate Endpoints and Genetic Sequencing in Cancer Care

February 17th 2017

Pam Mangat on the Future of Surrogate Endpoints and Genetic Sequencing in Cancer Care

Surrogate endpoints could eventually add to or replace clinical endpoints in determining a cancer treatment’s effectiveness, according to Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology. She also said that a deeper understanding of a patient’s genetic makeup and tumor biology in conjunction with new technologies will drive improvements in oncology care.

February 16th 2017

Advanced APMs and the Emerging Role of Immuno-Oncology Agents: Balancing Innovation and Value

Michael V. Seiden, MD, PhD Marcus Neubauer, MD Diana Verrilli

The shift to value-based care, concurrent with innovations in immune-based care, will create challenges in oncology. What should be the physician and manufacturer responsibility during these changing times?

February 16th 2017

Helping Cancer Patients and Caregivers Navigate Immunotherapy Treatment

Claire Saxton, MBA Joanne Buzaglo, PhD Sue Rochman, MA Alexandra Zaleta, PhD

Patients, caregivers, and providers need education on immunotherapy treatment, support in patient-provider communications as well as support in mitigating the financial impact of immunotherapy treatment.

February 16th 2017

Postmenopausal Weight Loss Cuts Risk of Endometrial Cancer by Half

Surabhi Dangi-Garimella, PhD

Observational findings from the Women’s Health Initiative study found that an intentional weight loss regimen by postmenopausal obese women can slash their risk of endometrial cancer by 29% to 56%.

Dr Marianne Fazen Discusses New Ways to Educate Employers on Value in Cancer Care

February 16th 2017

Dr Marianne Fazen Discusses New Ways to Educate Employers on Value in Cancer Care

Through the use of workshops and other productions, the Texas Business Group on Health educates employers on how they can maximize value through oncology care innovations like precision medicine, according to Marianne Fazen, PhD, president and CEO of the Texas Business Group on Health.

February 15th 2017

UCSF Researchers Identify Determinants of Coverage for Hereditary Cancer Panels

Surabhi Dangi-Garimella, PhD

A new study published in the Journal of the National Comprehensive Cancer Network dives deeper into understanding the major roadblocks to coverage of hereditary cancer panels.

February 15th 2017

Breast Cancer Survivors Report More Cognitive Impairment After Chemotherapy

Christina Mattina

A study of breast cancer survivors’ cognitive performance before and after chemotherapy sheds light on the problem of cancer-related cognitive impairment.

...

81 82 83 84 85 86 87 88 89

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions